Rebecca A. Gardner, MD

"I was drawn to the field of pediatric oncology because of the kids. It is an honor to be involved with patients and their families as we work toward curing their cancer."

  • Rebecca A. Gardner, MD, is an assistant professor in the Department of Pediatrics at the University of Washington, and attending physician at Seattle Children's Hospital.

    Her research focuses on the development of immunotherapy trials for the treatment of pediatric leukemia and lymphoma. The immune system can be a powerful tool in the treatment and eradication of pediatric malignancies. From advances in the lab, we are now able to genetically modify a person's own T cells to allow the T cells to specifically recognize and kill cancer cells.

    • Related Resources

    • Alison Bellevue, WA 07.26.17

      A great provider! She helped take care of our 4 year old son when he was very ill in the PICU. We appreciated her knowledge, care, and compassion.

    • Tom Ephrata, WA 03.01.17

      Dr. Gardner is a wonderful doctor. Our son, Trevor, was diagnosed in 2014 with leukemia. Dr. Gardner was on our team and provided excellent care during chemo and radiation treatment. She took extra time to answer our questions and allay our concerns about the radiation treatments. When Trevor relapsed last year, she went through all the options, helping us to ultimately settle on a Bone Marrow Transplant as the best course of treatment. She patiently answered all of our questions and made us feel included in his treatment plan. We feel very blessed to have had this amazing doctor guide Trevor's treatment.

  • Published Abstracts

    • Rebecca A. Gardner, MD, Gardner, RA, Reik, A, Berger, C, Terakura, S, Gregory, PD, Jensen, MC, Holmes, MC, Riddell, SR
      Disruption of Glucocorticoid Regulation in Therapeutic Human T Cells with Zinc Finger Nucleases
      Molecular Thearpy, 2010 : 18(S1)s240

    Other Publications

    • Gardner R, Wu D, Cherian S, Fang M, Hanafi LA, Finney O, Smithers H, Jensen MC, Riddell SR, Maloney DG, Turtle CJ
      Acquisition of a CD19 negative myeloid phenotype allows immune escape of MLL-rearranged B-ALL from CD19 CAR-T cell therapy.
      26907630 Blood, 2016 Feb. 23
    • Lee DW, Gardner R, Porter DL, Louis CU, Ahmed N, Jensen M, Grupp SA, Mackall CL
      Current concepts in the diagnosis and management of cytokine release syndrome.
      24876563 Blood, 2014 July 10 : 124(2)188-95 PMCID:PMC4093680
    • Gardner RA, Thomson B, Hawkins DS
      Substitution with doxorubicin for daunorubicin during induction for high risk pediatric acute lymphoblastic leukemia results in increased toxicity.
      23015453 Pediatric blood & cancer, 2012 Sept. 26
    • Terakura S, Yamamoto TN, Gardner RA, Turtle CJ, Jensen MC, Riddell SR
      Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells.
      22031866 Blood, 2012 Jan. 5 : 119(1)72-82 PMCID:PMC3251238
    • Losick VP, Schlax PE, Emmons RA, Lawson TG
      Signals in hepatitis A virus P3 region proteins recognized by the ubiquitin-mediated proteolytic system.
      12758177 Virology, 2003 May 10 : 309(2)306-19
    • Azzam HS, DeJarnette JB, Huang K, Emmons R, Park CS, Sommers CL, El-Khoury D, Shores EW, Love PE
      Fine tuning of TCR signaling by CD5.
      11313384 Journal of immunology (Baltimore, Md. : 1950), 2001 May 1 : 166(9)5464-72
    • DeJarnette JB, Sommers CL, Huang K, Woodside KJ, Emmons R, Katz K, Shores EW, Love PE
      Specific requirement for CD3epsilon in T cell development.
      9843989 Proceedings of the National Academy of Sciences of the United States of America, 1998 Dec. 8 : 95(25)14909-14 PMCID:PMC24549

  • Grant Title Grantor Amount Award Date
    Autologous T cells genetically modified to express a CD19 specific chimeric antigen receptor to treat pediatric relapsed acute lymphoblastic leukemia. Conquer Cancer Foundation July 1, 2013 - June 30, 2016
    Immunogenomics to Create New Therapies for High-Risk Childhood Cancers CHOP/St. Baldricks Foundation July 1, 2013 - June 30, 2018
    Autologous T cells genetically modified to express a CD19 specific chimeric antigen receptor to treat pediatric relapsed acute lymphoblastic leukemia. Conquer Cancer Foundation July 1, 2013 - June 30, 2016


Board Certification(s)

Pediatric Hematology-Oncology

Medical/Professional School

University of Maryland School of Medicine, Baltimore


Pediatrics, University of Utah School of Medicine, Salt Lake City


Hematology, University of Washington School of Medicine, Seattle

Research Focus Area

Cancer biology, Cancer